insights_auto
Why is GNLX up 2.40%?
Dive Deeperchevron_right
GNLX:NASDAQ
Genelux Corp
$2.56
arrow_upward
+2.40%(+0.060) 1D
Oct 9, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GNLX...
Open
$2.48
High
$2.57
Low
$2.47
Mkt. cap
115.83M
Avg. vol.
275.44K
Volume
0.00
52-wk high
$8.54
52-wk low
$2.29
EPS
-$0.87
Beta
0.59
Shares outstanding
45.24M
No. of employees
26
Open
$2.48
High
$2.57
Low
$2.47
Mkt. cap
115.83M
Avg. vol.
275.44K
Volume
0.00
52-wk high
$8.54
52-wk low
$2.29
EPS
-$0.87
Beta
0.59
Shares outstanding
45.24M
No. of employees
26
News stories
From web sources and news partners
TradingView
·
45 minutes ago
SPX: S&P 500 Nears Record as Traders Gear Up for Earnings, Inflation Data
Benzinga
·
25 minutes ago
Dow Jumps Over 400 Points, Records Weekly Gain: Investor Sentiment Improves, Fear & Greed Index Moves yo
https://www.ababnews.com/
·
35 minutes ago
Barchart points out that the average return of the S&P 500 after midterm elections since 1950 is 17.2%
FXLeaders
·
8 hours ago
Dow Jones and Nasdaq Futures Start Higher Ahead of US Inflation Data
Profile
Genelux Corporation is a publicly traded late clinical-stage company developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
About Genelux Corp
CEO-
Employees26
Founded2001
HeadquartersWestlake Village, California, United States
SectorBiotechnology
Websitegenelux.com